TY  - JOUR
AU  - Al-Monajjed, Rouvier
AU  - Boschheidgen, Matthias
AU  - Lakes, Jale
AU  - Krilaviciute, Agne
AU  - Radtke, Jan-Philipp
AU  - Schlemmer, Heinz-Peter
AU  - Bonekamp, David
AU  - Herkommer, Kathleen
AU  - Jahnen, Matthias
AU  - Gschwend, Jürgen E
AU  - Düx, Daniel
AU  - Wacker, Frank
AU  - Makowski, Marcus R
AU  - Sauter, Andreas
AU  - Kuczyk, Markus A
AU  - Harke, Nina
AU  - Debus, Jürgen
AU  - Grott, Christoph
AU  - Arsov, Christian
AU  - Seibold, Petra
AU  - Hadaschik, Boris
AU  - Giesel, Frederik
AU  - Kristiansen, Glenn
AU  - Antoch, Gerald
AU  - Becker, Nikolaus
AU  - Kaaks, Rudolf
AU  - Schimmöller, Lars
AU  - Albers, Peter
TI  - Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
JO  - European urology
VL  - 88
IS  - 3
SN  - 0302-2838
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2025-01143
SP  - 240-244
PY  - 2025
N1  - #EA:C130#LA:C130# / 2025 Sep;88(3):240-244
AB  - The optimal approach for prostate cancer (PC) screening, including the ideal starting age and most effective diagnostic method, remains under investigation. We evaluated the diagnostic performance of magnetic resonance imaging (MRI)-targeted biopsy (TBx) and systematic biopsy (SBx) in detecting clinically significant PC (csPC) in men aged 45-50 yr in PROBASE, a prospective, randomized trial of a risk-adapted screening strategy. A total of 525 participants with elevated prostate-specific antigen (≥3 ng/ml) underwent MRI followed by biopsy. Of the 209 PC cases detected, 148 (71
KW  - Fusion biopsy (Other)
KW  - Magnetic resonance imaging (Other)
KW  - Prostate cancer (Other)
KW  - Prostate-specific antigen (Other)
KW  - Risk-adapted screening (Other)
KW  - Ultrasound (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40461322
DO  - DOI:10.1016/j.eururo.2025.05.020
UR  - https://inrepo02.dkfz.de/record/301763
ER  -